Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2543 • ACR Convergence 2025
Severe Visual Impairment in Behçet Syndrome in Time: A Comparison of Four Time Periods
Mustafa Erdogan¹, Koray Tascilar², Yagmur Ersoya³, Alp Ozcan⁴, Mert Gurcan⁴, Talal Ammar⁴, Sinem Nihal Esatoglu⁵, Yesim Ozguler⁵, Gulen Hatemi⁵ and Hasan Yazici⁶, ¹Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Division of Rheumatology / Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Friedrich Alexander University of Erlangen Nuremberg, Universitätsklinikum Erlangen Department of Medicine ³, Rheumatology and Immunology, Erlangen, Germany, ³Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Department of Internal Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁶Academic Hospital, Istanbul, Turkey
Background/Purpose: There is consensus that the visual prognosis in Behçet syndrome (BS) uveitis has considerably improved in time (1-3). We wanted to better quantitate this…
Abstract Number: 2195 • ACR Convergence 2025
Enhancing MTX and LEF Safety for Immunosuppressed Women of Childbearing Age with Rheumatic Diseases
Angela Bobak¹, Rhea Sharma², Jordan Jackson³, Maritza Nary², Andrea Berger⁴, Lifang Zhang⁴ and Jonida Cote⁵, ¹Geisinger Medical Center Rheumatology Fellowship, Danville, PA, ²Geisinger Medical Center Internal Medicine Residency, Danville, PA, ³Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ⁴Geisinger Health System, Danville, PA, ⁵Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: The rates of contraceptive counseling and treatment in immunosuppressed women of childbearing age remain low in the United States, despite ACR's Reproductive Health Guidelines…
Abstract Number: 1465 • ACR Convergence 2025
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compan¹, Philip J. Mease², Lianne S. Gensler³, Martin Rudwaleit⁴, Yael Klionsky⁵, Jayne Stigler⁶, Erin Mancl⁷, Shirley Chen⁸, Jamie Urbanik⁹ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁵Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁶AbbVie, Round Lake, IL, ⁷AbbVie, Chicago, IL, ⁸AbbVie, Somerset, NJ, ⁹AbbVie, Grayslake, IL, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Treatment with the oral JAK inhibitor upadacitinib (UPA) has shown efficacy and safety in patients with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA,…
Abstract Number: 1321 • ACR Convergence 2025
Efficacy and safety of janus kinase inhibitors in diffuse interstitial lung disease in rheumatoid arthritis. Systematic review
Olga Compán¹, Marta Ibañez², Olga Martínez³, Carolina Cristina Chacón⁴, Ricardo López Pérez³, Borja Felices López³, Belén Miguel Ibáñez³, Laura Blanco⁴, Sergio Cimadevila Santiago³, Ana Isabel Turrión Nieves³, Manuel Cipriano Martin Martinez³, Cristina Hidalgo Calleja⁴, Carlos Montilla⁴ and Susana Gómez⁴, ¹Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain, ²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ³Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a relatively common serious extra-articular complication in rheumatoid arthritis (RA). Although there have been great advances, we do not…
Abstract Number: 1025 • ACR Convergence 2025
Association Between Rural-Urban Clinics and the Management of Adult Rheumatoid Arthritis in the United States
Megan Lorenz, Paxten Wahlund, Henry Elsenpeter, Abe Sahmoun and James Beal, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) improve symptom management and outcomes in rheumatoid arthritis (RA). While residence may influence management strategies and access to care,…
Abstract Number: 0790 • ACR Convergence 2025
Diabetes Risk in Psoriasis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs: Target Trial Emulation Using Nationwide Data
Arjun Mahajan¹, David Bates², Vinod Nambudiri³, Avery LaChance², Jeffrey Sparks⁴ and Evan Piette³, ¹Harvard Medical School, Boston, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis is a chronic inflammatory skin disease associated with increased risk of metabolic complications, such as diabetes mellitus. However, the impact of specific biologic…
Abstract Number: 0473 • ACR Convergence 2025
A Phase 2b Dose-Ranging Study of Peresolimab for Adults with RA
Jay Tuttle¹, Kirstin Griffing², Mark Genovese², Hyungmin Rha², So Young Park², Pia Yachi¹, Ajay Nirula¹, LANCE PFEIFER², Tami Jo Rayle², Jesus Abraham Simón-Campos³, Clifton Bingham⁴, Kevin Winthrop⁵, Daniel Aletaha⁶, Iain McInnes⁷, Yu Xue⁸, Yoshiya Tanaka⁹, Roy Fleischmann¹⁰, Paul Emery¹¹ and Michael Weinblatt¹², ¹Lilly Biotechnology Center, San Diego, CA, ²Eli Lilly and Company, Indianapolis, IN, ³Köhler & Milstein Research, UADY School of Medicine, Merida, Yucatan, Mexico, ⁴Johns Hopkins University, Baltimore, MD, ⁵Oregon Health & Science University, Portland, OR, ⁶Medical University Vienna, Wien, Austria, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ⁹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ¹¹University of Leeds, Leeds, England, United Kingdom, ¹²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Peresolimab, a humanized IgG1 mAb, activates programmed cell death protein 1. In a phase 2a study, peresolimab demonstrated efficacy in participants (pts) with RA…
Abstract Number: 0585 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic disease characterized by inflammatory low back pain and is often accompanied by inflammation of the peripheral joints and…
Abstract Number: 2445 • ACR Convergence 2025
Achievement of Treat to Target Measures With Upadacitinib in Patients With Systemic Lupus Erythematosus: Phase 2 Randomized SLEek Clinical Trial Results
Eric Morand¹, Joan Merrill², Martin Aringer³, Zahi Touma⁴, Richard Furie⁵, Karim Masri⁶, Christopher Saffore⁷, Ling Cheng⁸ and Ronald van Vollenhoven⁹, ¹Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ²Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ³University Medical Center, Dresden, Germany, ⁴University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., waukegan, IL, ⁸AbbVie, North, IL, ⁹Department of Rheumatology, Amsterdam University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Achievement of treat-to-target measures Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) has been associated with improved outcomes and…
Abstract Number: 2042 • ACR Convergence 2025
Safety and Effectiveness of the Use of Combined Therapy with bDMARDS and tsDMARDs in Immune-mediated Inflammatory Diseases
Natalia Lopez Juanes¹, Carlota Ureta¹, Marta Novella-Navarro¹, Irene Monjo Henry¹, Diana Peiteado¹, Alejandro Villalba¹, Laura Nuño², Victoria Navarro-Compan³, María Sanz¹, Mª ángeles Gonzalez¹, Cristina Suarez⁴, Agustin Remesal¹, Rosa Alcobendas⁵, Clara udaondo¹, Elena Sendagorta⁵, Alejandro Balsa¹, Eugenio de Miguel¹ and Chamaida Plasencia-Rodríguez¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario Puerta de Hierro, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁵La Paz University Hospital, Madrid, Spain
Background/Purpose: The combination of biological (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) has emerged as a promising approach to improve clinical outcomes in immune-mediated inflammatory diseases…
Abstract Number: 1459 • ACR Convergence 2025
Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
Shikha Singla¹, Linda Grinnell-Merrick², Weibin Bao³, Artem Zharkov⁴ and Abhijeet Danve⁵, ¹Medical College of Wisconsin, Milwaukee, WI, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: PsA is a chronic inflammatory disease characterized by joint pain, swelling and stiffness, and is often accompanied by cutaneous changes linked to psoriasis. Patients…
Abstract Number: 1311 • ACR Convergence 2025
Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study
Georges El Hasbani¹, Roslin George², Anne Shurtz¹, Cynthia Crowson³ and Elena myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Early and aggressive treatment of rheumatoid arthritis (RA) has been linked to improved remission rates, but achieving early and sustained remission remains a challenging…
Abstract Number: 0580 • ACR Convergence 2025
Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic disease that causes inflammation of the joints, entheses, spine, skin, and nails.1 While available advanced treatments (txs) for…
Abstract Number: 0757 • ACR Convergence 2025
The role of Methotrexate in the treatment of Giant Cell Arteritis: data from the ARTESER registry.
Pablo Muñoz-Martínez¹, Marta Domínguez-Álvaro², Lucia Otero³, Clara Moriano⁴, Julio Sánchez Martín⁵, Javier Narváez⁶, Eva Galíndez Agirregoikoa⁷, Javier Mendizábal⁸, lydia Abasolo Alcazar⁹, Javier Loricera¹⁰, Alejandro Muñoz¹¹, Santos Castañeda¹², rafeal Benito-Melero¹³, Carmen Larena¹⁴, Paula Estrada-Alarcón¹⁵, Carlos Galisteo¹⁶, Anne Riveros frutos¹⁷, Francisco Ortiz sanjuán¹⁸, Tarek Salman Montes¹⁹ and Ricardo Blanco²⁰, ¹Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Spanish Society of Rheumatology, Madrid, Spain, ⁴Hospital León, LEON, Castilla y Leon, Spain, ⁵Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Navarra Hospital, Pamplona, Spain, ⁹IdISSC. HCSC, Madrid, Madrid, Spain, ¹⁰Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ¹¹Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ¹²Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹³MD, barcelona, Spain, ¹⁴Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ¹⁵Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ¹⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ¹⁹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common large-vessel vasculitis, and its cornerstone treatment is the use of corticosteroids (CS). Various therapies have been…
Abstract Number: 0470 • ACR Convergence 2025
Characterization of Patients With Rheumatoid Arthritis Based on Distinct Patterns of Pain Improvement Following Treatment With Filgotinib: A Post Hoc Analysis of FINCH 1
Peter Taylor¹, Yoshiya Tanaka², Louis Dron³, Katrien Van Beneden⁴, Gerd Burmester⁵ and Bruno Fautrel⁶, ¹University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Cytel, Toronto, Canada, ⁴Alfasigma S.p.A., Bologna, Italy, ⁵Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁶Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: Janus kinase inhibitors have been shown to ameliorate pain as well as inflammation in patients with rheumatoid arthritis (RA). Pain response trajectories were modeled…

« Previous Page
1
…
4
5
6
7
8
…
48
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].